Obesity pharmacotherapy: options and uses in clinical practice

Published on January 12, 2017   50 min

Other Talks in the Series: Topical Talks

0:00
Hello, my name is Scott Kahan. I'm an Obesity Physician from the United States, Johns Hopkins Bloomberg School of Public Health. And I'll be speaking today about "Obesity Pharmacotherapy". I'll describe options that we have available and some of their uses in clinical practice to treat obesity. Before we get there, let's just start with a little bit of a broad description about obesity.
0:27
So here's an example, showing the extreme growth in obesity prevalence over the course of the past few decades in the United States. So as you can see, in 1985, prevalence in all states was either quite low or we didn't have data. So all of those states that have no color, that actually suggests that there's no surveillance system in place. So just three decades ago, many states didn't even count the issue with obesity. They weren't counting the data. They didn't have a surveillance system in place because they didn't think it was an important enough problem. The states that were counting, there were relatively low prevalences. On the other hand, when we go ahead just three decades, it's of course a very different story. On the one hand, there are no more states in white. Everybody is keeping track. Every state as well as every country worldwide is now keeping track. It's a big public health problem. Moreover, we don't see any of those same colors from 1985 because there are no states that have as low a prevalence, as there was in 1985. Now we have additional colors denoting much higher prevalences of obesity. Nationally, in the United States, there's about a 35% prevalence of obesity. And that is defined as a BMI greater than 30. And in many states the prevalence is quite higher.
Hide

Obesity pharmacotherapy: options and uses in clinical practice

Embed in course/own notes